{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=27",
    "query": {
      "intervention": "cohort 2",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 7390,
    "total_pages": 739,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:51:32.342Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02775812",
      "title": "Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-11-28",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 69,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 58 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02775812"
    },
    {
      "nct_id": "NCT02071537",
      "title": "Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Chloroquine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-05-13",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071537"
    },
    {
      "nct_id": "NCT02239354",
      "title": "A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "VC-01™ Combination Product",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "ViaCyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2014-09",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2022-03-24",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239354"
    },
    {
      "nct_id": "NCT02063594",
      "title": "Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NCTX (PEGylated Liposomal Iodixanol Injection)",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marval Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-10",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02063594"
    },
    {
      "nct_id": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Triple Negative Breast Cancer",
        "HR+/HER2- Breast Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2016-12-19",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983045"
    },
    {
      "nct_id": "NCT04126031",
      "title": "Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gram-negative Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        },
        {
          "name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "88 Days",
        "sex": "ALL",
        "summary": "0 Days to 88 Days"
      },
      "enrollment_count": 48,
      "start_date": "2020-01-14",
      "completion_date": "2022-12-30",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126031"
    },
    {
      "nct_id": "NCT04914351",
      "title": "HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "HY-0102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai HyaMab Biotech Co.,Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-05-03",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Las Vegas, Nevada • Tyler, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04914351"
    },
    {
      "nct_id": "NCT00310895",
      "title": "Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor Malignancies"
      ],
      "interventions": [
        {
          "name": "Imetelstat Sodium (GRN163L)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Geron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2006-03",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Detroit, Michigan",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310895"
    },
    {
      "nct_id": "NCT04226131",
      "title": "MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Healthy Controls"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "OTHER"
        },
        {
          "name": "Disease Activity (DAS-28) Assessment",
          "type": "OTHER"
        },
        {
          "name": "Skeletal Muscle Mitochondrial Respiratory Capacity",
          "type": "OTHER"
        },
        {
          "name": "Muscle Biopsy",
          "type": "OTHER"
        },
        {
          "name": "Body Composition",
          "type": "OTHER"
        },
        {
          "name": "Cardiopulmonary Exercise Test (CPET)",
          "type": "OTHER"
        },
        {
          "name": "Strength Testing",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Skeletal Muscle Biomechanical Property Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-09-09",
      "completion_date": "2023-07-07",
      "has_results": false,
      "last_update_posted_date": "2023-07-13",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04226131"
    },
    {
      "nct_id": "NCT06007937",
      "title": "A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Metastatic",
        "Recurrent"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2023-08-17",
      "completion_date": "2028-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-19T04:51:32.342Z",
      "location_count": 6,
      "location_summary": "Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more",
      "locations": [
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007937"
    }
  ]
}